We at the Institute for Diabetes Discovery are committed to making a positive difference in the lives of people suffering from diabetes and its devastating complications through novel drug discovery. Our experienced scientists work continuously on our defined areas of research focus: diabetic complications, insulin resistance, diabetic dyslipidemia, obesity, and glycation.

Our science team has proved its extensive knowledge of drug discovery of novel treatments and therapeutics for diabetes. With IDD 676 (lidorestat), a potent aldose reductase inhibitor (ARI) for diabetic complications, we filed an IND within 30 months of commencing discovery. Using the latest in biology, chemistry, and discovery resources available, our science management will continue our commitment to improving the lives of those with diabetes.